Participants
The following participants are currently involved in organizing CIP Proficiency Panels and Workshops:
N. Bidmon, Department of Internal Medicine III, University of Mainz and TRON gGmbH, Mainz, Germany
S. Brandau, University Hospital, Essen, Germany
V. Bronte, Verona University Hospital and Department of Pathology, Verona, Italy
R. Challis, Cancer Sciences Division, Southampton University Hospitals, Southampton, United Kingdom
A. Chandran, Department of Immunology, University of Tübingen, Tübingen, Germany
L. Chudley, Cancer Sciences Division, Southampton University Hospitals, Southampton, United Kingdom
S.R. Hadrup, Technical University of Denmark, National Veterinary Institute, Copenhagen
S. Heidu, Department of Immunology, University of Tübingen, Tübingen, Germany
C. Gouttefangeas, Department of Immunology, University of Tübingen, Tübingen, Germany
P. Kvistborg, Division of Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
K. McCann, Cancer Sciences Division, Southampton University Hospitals, Southampton, United Kingdom
S. Mandruzzato, Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy
C. H. Ottensmeier, Cancer Sciences Division, Southampton University Hospitals, Southampton, United Kingdom
S. Santegoets, Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands
K. Tier, Cancer Sciences Division, Southampton University Hospitals, Southampton, United Kingdom
S. H. van der Burg, Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands
M. J. P. Welters, Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands
Proficiency Panel / Workshop Participants 2005-2016
To date, seventy-seven academic laboratories or companies have participated in CIP proficiency panels. Participants are mainly located in European countries (Belgium, Denmark, France, Germany, Italy, The Netherlands, Norway, Poland, Spain, Sweden, Switzerland, UK). Following a cooperative action with CIC, thirteen labs from the USA have joined our last panels.
Acknowledgement - CIP Members and Panel Participants - CIP members 2013-2016
M. Aigner, Department of Haematology and Oncology, Internal Medicine 5, Erlangen, Germany
S. Ait-Yahia, Platine, European Immunomonitoring Platform, Centre d’Infectiologie, Lyon, France
C. Alanio, Center for Human Immunology, Pasteur Institute, Paris, France
M. Albert, Center for Human Immunology, Pasteur Institute, Paris, France
J. Albrecht, Institute of Molecular Immunology, Helmholtz Center, Munich, Germany
M.H. Andersen, Center for Cancer Immune Therapy, Herlev University Hospital, Herlev, Denmark
S. Andersson, Karolinska Institutet, Center for Infectious Medicine (CIM), Stockholm, Sweden
N. Anfossi, Platine, European Immunomonitoring Platform, Centre d’Infectiologie, Lyon, France
K. Arnkværn, Dept. of Immunology, Institute of Cancer Research, Oslo University Hospital, Oslo, Norway
M. Assenmacher, Miltenyi Biotec, Bergisch Gladbach, Germany
S. Attig, Department of Internal Medicine III, University of Mainz and TRON gGmbH, Mainz, Germany
C. Bain, Platine, European Immunomonitoring Platform, Centre d’Infectiologie, Lyon, France
T. Bauer, Institute of Virology and Helmholtz Center, Munich, Germany
P. Baumgartner, Division of Clinical OncoImmunology, Lausanne, Switzerland
A. Beck, Center for Immunotherapy, Roswell Park Cancer Institute, Buffalo, USA
N. Bidmon, Department of Internal Medicine III, University of Mainz and TRON gGmbH, Mainz, Germany
S. Brandau, Otorhinolaryngology, University Hospital Essen, Germany
M. Braun, Division of Clinical OncoImmunology, Lausanne, Switzerland
C. M. Britten, TRON gGmbH and BioNTech RNA Pharmaceuticals GmbH, Mainz, Germany; now GSK, Stevenage, UK
L. Brix, Immudex, Copenhagen, Denmark
K. Bruderek, Otorhinolaryngology, University Hospital Essen, Germany
M. Buffo, Immune Monitoring Lab, Hillman Cancer Center, Pittsburgh, USA
L. Butterfield, Immune Monitoring Lab, Hillman Cancer Center, Pittsburgh, USA
J. Caterini, Sanofi-Pasteur, Marcy l´étoile, France
C. Caillet, Sanofi-Pasteur, Marcy l´étoile, France
G. Casorati, Experimental Immunology Unit, San Raffaele Scientific Institute, Milan, Italy
A. Cazaly, Cancer Sciences Division, Southampton University Hospitals, Southampton, UK
V. Cecconi, Experimental Immunology Unit, San Raffaele Scientific Institute, Milan, Italy
A. Cerwenka, Department of Tumor Immunology, DKFZ, Heidelberg, Germany
R. Challis, Cancer Sciences Division, Southampton University Hospitals, Southampton, UK
L. Chudley, Cancer Sciences Division, Southampton University Hospitals, Southampton, UK
A. Coleman, Cancer Sciences Division, Southampton University Hospitals, Southampton, UK
T. Condamine, The Wistar Institute, Philadelphia, USA
G. Convertino, Instituto Nazionale Tumori, Milan, Italy
G. Cook, Leeds Institute of Cancer and Pathology, St-James University Hospital, Leeds, UK
N. Cools, Experimental Immunology, Faculty of Medicine, Antwerp, Belgium
J. Currier, Henry Jackson Foundation, Rockville, USA
V. Damuzzo, Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy
P. Dellabona, Experimental Immunology Unit, San Raffaele Scientific Institute, Milan, Italy
M. Delso Vallejo, Miltenyi Biotec, Bergisch Gladbach, Germany
E. Derhovanessian, Center for Medical Research, University of Tübingen, Tübingen, Germany. Now Department of Internal Medicine III, University of Mainz and TRON GmbH, Mainz, Germany
J. de Vries, Centre for Molecular Life Sciences, Nijmegen, The Netherlands
C. Diaz, University of Miami, Miami, USA
G. Di Lullo, Tumor Immunology Unit, San Raffaele Scientific Institute, Milan, Italy
C. Dobano, CRESIB, Barcelona, Spain
H. Dockrell, London School of Hygiene & Tropical Medicine, London, UK
R. Dolcetti, Cancer Bio-Immunotherapy Unit, National Cancer Institute, Aviano, Italy
J. Eckl, Medigen AG, Munich, Germany
J. Enzor, Duke CFAR Flow Core Facility, Durham, USA
C. Falk, Immune Monitoring Unit, NCT and Institute for Immunology, Heidelberg, Germany. Now Institute for Transplantation Immunology, Hanover Medical School, Hanover, Germany
M. Fassnacht, Department of Internal Medicine I, University of Würzburg, Würzburg, Germany
G. Ferrari, Duke University Medical Center, Durham, USA
H. Filbert, Department of Internal Medicine III, University of Mainz and TRON gGmbH,Mainz, Germany
J. Finke, Cleveland Clinic, Cleveland, Ohio, USA
S. Flindt, PEI, Langen, Germany
P. Frati, Instituto Nazionale Tumori, Milan, Italy
W. Freber, Biosys, Karben, Germany
C. Frömmel, Institute of Molecular Immunology, Helmholtz Center, Munich, Germany
S. Gallichan, Sanofi-Pasteur, Marcy l´étoile, France
D. Gabrilovich, The Wistar Institute, Pennsylvania
K. Giannopoulos, Clinical Immunology Department, Medical University of Lublin, Lublin, Poland
G. Gaudernack, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo, Norway
C. Gouttefangeas, Department of Immunology, University Hospital,Tübingen, Germany
M. Granzin, Miltenyi Biotec, Bergisch Gladbach, Germany
T. Greten, Gastrointestinal Malignancy Section, NCI, Bethesda, USA
S. Gross, Department of Dermatology, University of Erlangen, Erlangen, Germany
S.R. Hadrup, Technical University of Denmark, National Veterinary Institute, Copenhagen, Denmark
A. Harenberg, Sanofi-Pasteur, Marcy l´étoile, France
M. Hasan, Center for Human Immunology, Pasteur Institute, Paris, France
S. Heidu, Dept of Immunology, Tübingen, Germany
T. Hinz, PEI, Langen, Germany
H.J. Hoel, Section for Immunotherapy, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo, Norway
H. Hong, Curevac, Tübingen, Germany
J. Hosse, Tumor Immunology, University of Munich, Munich, Germany
V. Huppert, Miltenyi Biotec, Bergisch Gladbach, Germany
M. Idorn, Center for Cancer Immune Therapy, Department of Oncology, Herlev University Hospital, Herlev, Denmark
S. E. M. Inderberg, Section for Immunotherapy, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo, Norway
T. Jakobsen, Immudex, Copenhagen, Denmark
C. Jandus, Division of Clinical OncoImmunology, Lausanne, Switzerland
D. Joseph-Pietra, Cancer Sciences Division, Southampton University Hospitals, Southampton, UK
E. Kämpgen, Department of Dermatology, University of Erlangen, Erlangen, Germany.
Now Dermatologikum Berlin, Germany
A. K. Kaskel, Department of Hematology/Oncology, Freiburg University Medical Center, Freiburg, Germany
F. Kern, Division of Medicine, Brighton and Sussex Medical School, Brighton, UK
R. Kiessling, Immune and GeneTherapy Unit Karolinska Institutet, Stockholm, Sweden
S. Kloess, Hanover Medical School, GMP-Development Unit, Hanover, Germany
S. Koch, Department of Experimental Immunology, Academic Medical Center, Amsterdam, The Netherlands. Now Curevac, Tübingen, Germany
T. M. S. Køllgaard, Center for Cancer Immune Therapy, Department of Oncology, Herlev University Hospital, Herlev, Denmark
F. Korangy, Gastrointestinal Malignancy Section, NCI, Bethesda, Maryland, USA
C. Krupka, Klinikum der Universität München, Laboratory for Leukemia Diagnostic, Munich, Germany
C. Kucala, Center for Immunotherapy, Roswell Park Cancer Institute, Buffalo, USA
P. Kvistborg, Netherlands Cancer Institute, Amsterdam, The Netherlands
K. Laske, Department of Immunology, University of Tübingen, Tübingen, Germany; now Immatics Biotechnologies, Tübingen, Germany
F. Legrand, BN Immunotherapeutics, Mountain View, USA
W. Leisgang, Department of Dermatology, University of Erlangen, Erlangen, Germany
K. Lenders, Experimental Immunology, Faculty of Medicine, Antwerp, Belgium
V. Lennerz, Department of Internal Medicine III, University of Mainz, Mainz, Germany
A. Letsch, Department of Hematology and Oncology, Charité, Berlin, Germany
F. Lichtenegger, III Medical Dept, Munich, Germany
E. Lion, Antwerp University Hospital, Center for Cellular Therapy and Regenerative Medicine, Antwerp, Belgium
K. Lislerud, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo, Norway
A. Mackensen, Department of Haematology and Oncology, Erlangen, Germany
R. Maier, Research Department, Kantonal Hospital St. Gallen, St. Gallen, Switzerland
K. Malmberg, Karolinska Institutet, Center for Infectious Medicine (CIM), Stockholm, Sweden
S. Man, Medical Biochemistry and Immunology, Cardiff University, Cardiff, UK
A. Mander, Cancer Sciences Division, Southampton University Hospitals, Southampton, UK
S. Mandruzzato, Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy
J. Matsuzaki, Center for Immunotherapy, Roswell Park Cancer Institute, NY, USA
D. Maurer, Immatics Biotechnologies, Tübingen, Germany
K. McCann, Cancer Sciences Division, Southampton University Hospitals, Southampton, UK
A.A. Melcher, Leeds Institute of Cancer and Pathology, St-James University Hospital, Leeds, UK
R. Melsert, Sanquin, Amsterdam, The Netherlands
R. Mendrzyk, Immatics Biotechnologies, Tübingen, Germany
A. Mesenholl, Mabtech, Nacka Strand, Sweden
G. Moncunill, CRESIB, Barcelona, Spain
D. Morelli, Moffitt Cancer Center, Tampa, USA
E. Mottez, Centre for Human Immunology, Pasteur Institute, Paris, France
M. Navarette, Department of Hematology/Oncology, Freiburg University Medical Center, Freiburg, Germany. Now Magallanes University Medical School, Punta Arenas, Chile
M. Neuenbahn, Institute of Molecular Immunology, Helmholtz Center, Munich, Germany
M. Niemöller, Miltenyi Biotec, Bergisch Gladbach, Germany
S. Nierkens, Translational Immunology, Utrecht University Medical Center, The Netherlands
H. Nijman, Department of Obstetrics and Gynaecology, UMCG, Groningen, The Netherlands
M. Nystrom, Immune and Gene Therapy Unit Karolinska Institutet, Stockholm, Sweden
E. Nössner, Institute of Molecular Immunology, Helmholtz Center, Munich, Germany
N. Nougarède, Sanofi-Pasteur, Marcy l´etoile, France
O. Oberschmidt, Hanover Medical School, GMP-Development Unit, Hanover, Germany
A. Ochoa, Louisiana State University, New Orleans, USA
R. Offringa, Molecular Oncology of Gastrointestinal Tumors, Heidelberg, Germany
C. H. Ottensmeier, Cancer Sciences Division, Southampton University Hospitals, Southampton, UK
J. Pahl, Department of Tumor Immunology, DKFZ, Heidelberg, Germany
P. Palluch, University Hospital Munich, III Medical Dept, Munich, Germany
A. Paschen, Skin Cancer Unit of the German Cancer Research Center, University Hospital Mannheim, Mannheim, Germany. Now Department of Dermatology, University Hospital Essen, Essen, Germany
S. Paulie, Mabtech, Nacka Strand, Sweden
G. Pawelec, Center for Medical Research, University of Tübingen, Tübingen, Germany
Y. Peretz, Caprion ImmuneCarta Services, Montreal, Canada
H. Petersen, Immudex, Copenhagen, Denmark
D. Philips, Dept of Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
Y. Pico de Coana, Immune and Gene Therapy Unit, Karolinska Institutet, Stockholm, Sweden
H. Pohla, Tumor Immunology, University of Munich, Munich, Germany
I. Poschke, Molecular Oncology of Gastrointestinal Tumors, Heidelberg, Germany
J. Pots, Tumor Immunology, Centre for Molecular Life Sciences, Nijmegen, The Netherlands
X. Préville, Transgene, Illkirch- Graffenstaden, France
R. Preyer, AID Autoimmun Diagnostika, Strassberg, Germany
P. Prinz, Trianta Immunotherapies GmbH, Martinsried, Germany
M.P. Protti, Tumor Immunology Unit, Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Institute, Milan, Italy
J. Pufnock, Dendreon corporation, Seattle, USA
L. Puyol, CRESIB, Barcelona, Spain
R. Rae, Department of Internal Medicine III, University of Mainz/TRON gGmbH, Mainz, Germany
M. Radsack, Department of Immunology, University of Mainz, Mainz, Germany
A. M Rasmussen, Section for Immunotherapy, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo, Norway
G. Rauser, Miltenyi Biotec, Bergisch Gladbach, Germany
A. Richter, Miltenyi Biotec, Bergisch Gladbach, Germany
L. Rivoltini, Instituto Nazionale Tumori, Milan, Italy
D. Riemann, Institute of Medical Immunology, Martin Luther University, Halle, Germany
L. Rogge, Center for Human Immunology, Pasteur Institute, Paris, France
P. Romero, Division of Clinical OncoImmunology, Ludwig Center for Cancer Research, Lausanne, Switzerland
R. Rooke, Transgene, Illkirch- Graffenstaden, France
N. Scharenborg, Tumor Immunology, Centre for Molecular Life Sciences, Nijmegen, The Netherlands
B. Scheel, Curevac, Tübingen, Germany
C. Scheibenbogen, Department of Hematology and Oncology, Charité, Berlin, Germany
D. Schendel, Medigen AG, Munich, Germany
H. Schild, Department of Immunology, University of Mainz, Mainz, Germany
W. Schingler, Oxford BioMedica UK Ltd, Oxford, UK
F. Schlott, Technische Universität München, Institut für med. Mikrobiologie, Immunologie und Hygiene, Munich, Germany
A. Schmitt, Department of Internal Medicine III, University of Rostock, Rostock, Germany
M. Schmitt, Department of Internal Medicine III, University of Rostock, Rostock, Germany.
Now Department of Haematology, Heidelberg, Germany
M. Schmitt-Haendle, Department of Dermatology, University of Erlangen, Erlangen, Germany
M. Schmitz, Institute for Immunology, Technical University Dresden, Germany
G. Schöllhorn, AID Autoimmun Diagnostika, Strassberg, Germany
G. Schreibelt, Centre for Molecular Life Sciences, Nijmegen, The Netherlands
E. Schultz, Department of Dermatology, University of Marburg, Marburg, Germany
T. Schumacher, Dept of Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
B. Seliger, Institute of Medical Immunology, Martin Luther University, Halle, Germany
P. Serafini, University of Miami, Miami, USA
V. Sheng, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo, Norway
I. Shevchenko, Dermato-Oncology Dept, DKFZ, Heidelberg, Germany
S. Singh, Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands
S. Smith, London School of Hygiene & Tropical Medicine, London, UK
D. Speiser, Ludwig Institute of Cancer Research, Lausanne, Switzerland
S. Stevanovic, Department of Immunology, University of Tübingen, Tübingen, Germany
P. T. Straten, Center for Cancer Immune Therapy, Herlev University Hospital, Herlev, Denmark
M. Subklewe, Klinikum der Universität München, III Medical Department and Laboratory for Leukemia Diagnostic,
Munich, Germany
K. Tier, Cancer Sciences Division, Southampton University Hospitals, Southampton, UK
M. Toebes, Dept of Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
C. Tosch, Transgene, llkirch- Graffenstaden, France
E. Ullrich, LOEWE Center for Cell and Gene Therapy Frankfurt and Department of Hematology & Oncology of the Children’s Hospital, Frankfurt, Germany
L. Umansky, Immune Monitoring Unit, NCT and Institute for Immunology, Heidelberg, Germany
V. Umansky, Dermato-Oncology Dept, DKFZ, Heidelberg, Germany
S. H. van der Burg, Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands
M. van der Rakt, Tumor Immunology, Centre for Molecular Life Sciences, Nijmegen, The Netherlands
W. van Esch, Sanquin, Amsterdam, The Netherlands
R. van Lier, Experimental Immunology, Amsterdam, The Netherlands
A. Vefferstad, Institute of Cancer Research, Oslo University Hospital, Norway
H. Veelken, Department of Hematology and Oncology, Freiburg University Medical Center, Freiburg, Germany. Now Department of Hematology, Leiden University Medical Centre, Leiden, The Netherlands
A. Vefferstad, Institute for Cancer Research, Oslo, Norway
L. Veron, Platine, European Immunomonitoring Platform, Centre d’Infectiologie, Lyon, France
S. Vertuani, Immune and Gene Therapy Unit, Karolinska Institutet, Stockholm, Sweden
V. Visconti, Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands
M. Volkmar, Molecular Oncology of Gastrointestinal Tumors, Heidelberg, Germany
S. Walter, Immatics US Inc., Houston, USA
R. Wehner, Institute for Immunology, Technical University Dresden, Germany
M. J. P. Schoenmaekers-Welters, Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands
E.J. West, Leeds Institute of Cancer and Pathology, St-James University Hospital, Leeds, UK
M. Wiesinger, Department of Dermatology, University of Erlangen, Erlangen, Germany
E. Wilson, Leeds Institute of Cancer and Pathology, St-James University Hospital, Leeds, UK
G. Winckels, Miltenyi Biotec, Bergisch Gladbach, Germany
T. Wölfel, Department of Internal Medicine III, University Mainz, Mainz, Germany
H. Zelba, Center for Medical Research, Tübingen, Germany. Now Institute for Cell Biology, Department of Immunology, University Hospital, Tübingen, Germany
F. Zhao, Skin Cancer Unit of the German Cancer Research Center, University Hospital Mannheim, Mannheim, Germany. Now Department of Dermatology, University Hospital, Essen, Germany
